Focusing on Macrophages: Therapeutic Strategies for Diabetic Kidney Disease

Stephens Jat^*
*Correspondence: Stephens Jat, Department of Nephrology, University of Sydney, Sydney, Australia, Email:

Keywords

Diabetic kidney disease • Macrophage • Drug delivery

Introduction

Diabetic kidney disease is a severe complication of diabetes mellitus and a leading cause of end-stage renal disease worldwide. Despite advancements in treatment, the management of DKD remains challenging, highlighting the need for novel therapeutic approaches. Recently, there has been growing interest in targeting macrophages, key immune cells implicated in the pathogenesis of DKD, as a promising avenue for intervention. This article explores the role of macrophages in DKD and discusses emerging therapeutic strategies aimed at modulating their function to mitigate renal damage and improve patient outcomes.

Literature Review

Macrophages play a central role in the pathogenesis of DKD by promoting inflammation, fibrosis, and tissue injury within the kidney. In response to hyperglycemia and metabolic dysregulation, macrophages infiltrate the renal parenchyma, where they produce pro-inflammatory cytokines, reactive oxygen species, and profibrotic mediators, contributing to glomerular and tubulointerstitial damage. Furthermore, macrophages can undergo phenotypic changes, transitioning between pro-inflammatory (M1) and reparative (M2) states, with dysregulated polarization exacerbating renal injury in DKD [1].

Discussion

Therapeutic strategies aimed at targeting macrophages in DKD encompass a range of approaches, including modulation of macrophage recruitment, polarization, and function. Inhibition of chemotactic signals, such as monocyte chemoattractant protein-1 (MCP-1) and its receptor C-C chemokine receptor type 2 (CCR2), has shown promise in attenuating macrophage infiltration and renal inflammation in preclinical models of DKD. Additionally, agents promoting macrophage polarization towards an anti-inflammatory M2 phenotype, such as interleukin-4 and IL-13, have demonstrated renoprotective effects by suppressing inflammation and fibrosis. Recent advancements in drug delivery technologies have facilitated the development of targeted therapies aimed specifically at macrophages. Nanoparticle-based drug delivery systems can selectively deliver therapeutic agents to macrophages within the kidney, minimizing off-target effects and enhancing therapeutic efficacy. Moreover, cell-based therapies, including mesenchymal stem cell transplantation, hold promise for modulating macrophage activity and promoting tissue repair in DKD. MSCs exert immunomodulatory effects through paracrine signaling, leading to macrophage polarization towards an anti-inflammatory phenotype and amelioration of renal injury. Despite the potential of targeting macrophages as a therapeutic strategy for DKD, several challenges remain [2].

These include the need for precise targeting of macrophages within the kidney, optimization of drug delivery systems, and identification of biomarkers to monitor treatment response. Furthermore, the heterogeneity of macrophage populations and their dynamic response to microenvironmental cues necessitate a nuanced understanding of macrophage biology in DKD. Diabetic kidney disease also known as diabetic nephropathy, is a serious complication of diabetes mellitus and a leading cause of chronic kidney disease) worldwide. It develops gradually over many years, affecting individuals with both type 1 and type 2 diabetes. Understanding the underlying causes, recognizing the symptoms, and exploring treatment options are crucial for managing DKD effectively. This article provides an overview of DKD, its risk factors, clinical manifestations, and available treatment modalities. The primary cause of DKD is prolonged exposure to high blood sugar levels, which damages the small blood vessels in the kidneys' glomeruli, impairing their function over time. Other factors contributing to DKD development include hypertension, dyslipidemia, genetic predisposition, and lifestyle factors such as smoking and obesity. Additionally, certain ethnic groups, such as African Americans, Hispanics, and Native Americans, have a higher risk of developing DKD [3,4].

DKD typically progresses silently over many years, often without noticeable symptoms in the early stages. However, as the disease advances, individuals may experience symptoms such as persistent proteinuria (protein in the urine), hematuria (blood in the urine), swelling of the ankles, fatigue, nausea, and unexplained weight loss. If left untreated, DKD can progress to end-stage renal disease requiring dialysis or kidney transplantation for survival. Diagnosing DKD involves a combination of clinical assessment, laboratory tests, and imaging studies. Urine tests, including urine albumin-to-creatinine ratio and urine dipstick analysis, help detect proteinuria and hematuria, while blood tests measure kidney function by assessing serum creatinine and estimating glomerular filtration rate (eGFR). Imaging modalities such as ultrasound may be used to evaluate kidney size and structure. Management of DKD focuses on controlling blood sugar levels, blood pressure, and cholesterol levels to slow the progression of kidney damage and reduce the risk of complications. Lifestyle modifications, including dietary changes, regular exercise, smoking cessation, and weight management, are essential components of DKD management. Additionally, medications such as angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers are commonly prescribed to lower blood pressure and reduce proteinuria in individuals with DKD [5,6].

Conclusion

Targeting macrophages represents a promising therapeutic approach for DKD, offering the potential to attenuate inflammation, fibrosis, and renal injury. By modulating macrophage recruitment, polarization, and function, novel therapeutic strategies aim to mitigate the progression of DKD and improve patient outcomes. Continued research efforts focused on understanding macrophage biology, developing targeted therapies, and overcoming translational challenges are essential for realizing the full potential of macrophage-targeted interventions in DKD management.

Acknowledgement

None.

Conflict of Interest

There are no conflicts of interest by author.

References

1. Hoste, Eric AJ, Sean M. Bagshaw, Rinaldo Bellomo and Cynthia M. Cely, et al. "Epidemiology of acute kidney injury in critically ill patients: The multinational AKI-EPI study." Intensive Care Med 41 (2015): 1411-1423.

Google Scholar, Crossref, Indexed at

2. Wald, Ron, Robert R. Quinn, Jin Luo and Ping Li, et al. "Chronic dialysis and death among survivors of acute kidney injury requiring dialysis." Jama 302 (2009): 1179-1185.

Google Scholar, Crossref, Indexed at

3. See, Emily J., Kushani Jayasinghe, Neil Glassford and Michael Bailey, et al. "Long-term risk of adverse outcomes after acute kidney injury: A systematic review and meta-analysis of cohort studies using consensus definitions of exposure." Kidney Int 95 (2019): 160-172.

Google Scholar, Crossref, Indexed at

4. Thakar, Charuhas V., Annette Christianson, Ron Freyberg and Peter Almenoff, et al. "Incidence and outcomes of acute kidney injury in intensive care units: A Veterans Administration study." Crit Care Med 37 (2009): 2552-2558.

Google Scholar, Crossref, Indexed at

5. Uchino, Shigehiko, John A. Kellum, Rinaldo Bellomo and Gordon S. Doig, et al. "Acute renal failure in critically ill patients: A multinational, multicenter study." Jama 294 (2005): 813-818.

Google Scholar, Crossref, Indexed at

6. Meersch, Melanie, Raphael Weiss, Christian Strauß and Felix Albert, et al. "Acute kidney disease beyond day 7 after major surgery: A secondary analysis of the EPIS-AKI trial." Intensive Care Med (2024): 1-11.

Google Scholar, Crossref, Indexed at